Revvity
- Market cap
- 16.46B
- P/E (TTM)i
- 70.94
- P/Bi
- 2.28
- EPSi
- 2.07
- Div yieldi
- 0.19%
- 52W posi
- 78%
Anonymous reader poll. Unscientific, not investment advice.
About Revvity
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.
- Founded
- 1937
- CEO
- Dr. Prahlad R. Singh, PhD
- Employees
- 11,000
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-27
- Website
- revvity.com
Company profile
- Exchange
- US
- Symbol
- RVTY
- Market-cap rank
- #1032
- Listing date
- 1970-01-01
- Market cap
- 16.46B
- Float cap
- 15.12B
- Shares out
- 111.59M
- Float shares
- 102.49M
Sectors & themes
Quote time 2026-10-08 10:10:53 · For reference only, not investment advice and not tailored to your situation.